Compare APPF & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | BLTE |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.6B |
| IPO Year | 2015 | 2021 |
| Metric | APPF | BLTE |
|---|---|---|
| Price | $169.90 | $160.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $286.33 | $198.00 |
| AVG Volume (30 Days) | ★ 282.5K | 133.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $950,822,000.00 | N/A |
| Revenue This Year | $19.69 | N/A |
| Revenue Next Year | $16.70 | $492.11 |
| P/E Ratio | $128.42 | ★ N/A |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $142.73 | $56.68 |
| 52 Week High | $325.90 | $200.00 |
| Indicator | APPF | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 44.01 |
| Support Level | $161.13 | $157.63 |
| Resistance Level | $191.16 | $161.28 |
| Average True Range (ATR) | 6.56 | 7.07 |
| MACD | 2.18 | -0.59 |
| Stochastic Oscillator | 76.91 | 10.75 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.